GENE ONLINE|News &
Opinion
Blog

2025-11-29|

m6A Modification Found to Enhance Stability of CACNA1A Gene Linked to Ovarian Cancer Progression

by GOAI
Share To

A recent study has identified a significant connection between N6-methyladenosine (m6A) modification and ovarian cancer, specifically highlighting its influence on the stability of the CACNA1A gene. Researchers found that m6A modification plays a critical role in regulating the expression of CACNA1A, which is associated with the progression of ovarian cancer. The findings provide new insights into how molecular mechanisms contribute to malignancies.

The study focused on understanding how m6A, a chemical modification of RNA, affects gene stability and expression in cancer cells. Researchers observed that m6A modifications enhanced the stability of CACNA1A transcripts, leading to increased levels of this gene in ovarian cancer tissues. This upregulation was linked to tumor growth and progression. The research underscores the importance of epigenetic modifications like m6A in influencing cancer-related genes and their potential role in disease development.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: November 29, 2025

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Author
Related Post
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
LATEST
AI-Driven Healthcare Transformation at Healthcare Expo Taiwan 2025
2025-12-05
How AWS Cloud Is Transforming Global Smart Healthcare and Trusted Research Environments
2025-12-03
MedTex 2025: Taiwan as Gateway for AI-Driven Medical Innovation and Global Capital
2025-12-03
FDA CBER Director Vinay Prasad Issues November 2025 Memo Addressing Vaccine Development and Regulatory Challenges
2025-12-03
FDA to Review 16 Drug Applications Including 8 New Molecular Entities by Year-End
2025-12-03
Stephen Durso Named CEO of Altimmune Inc. as Vipin Garg Steps Down
2025-12-03
Janux Therapeutics Shares Halve Despite Positive Phase I Trial Results for Solid Tumor Therapy
2025-12-03
EVENT
2025-12-06
The 67th ASH Annual Meeting and Exposition
Orlando, Florida, USA
2025-12-04
2025 Healthcare+ Expo Taiwan
Taipei, Taiwan
Scroll to Top